The earnings call highlighted significant progress in clinical trials and a strong financial position, with increased revenue and continued pipeline expansion. However, the company also reported a net loss, though slightly improved from the previous year, and a decrease in R&D expenses.

Company Guidance

During AbCellera's Second Quarter 2025 Business Update Conference Call, the company provided comprehensive guidance on its clinical and financial progress. Key highlights included the initiation of Phase I clinical trials for two lead antibody candidates, ABCL635 and ABCL575, with Health Canada authorization. ABCL635 targets moderate to severe vasomotor symptoms, with a primary endpoint of safety and a secondary endpoint of pharmacokinetics, while ABCL575 focuses on atopic dermatitis with potential in broader autoimmune indications. The company reported approximately $750 million in available liquidity, including $580 million in cash and equivalents. Revenue for the quarter was approximately $17 million, a significant increase from $7 million in the same quarter of 2024, largely due to a one-off $10 million licensing fee. AbCellera anticipates initial safety and efficacy data for ABCL635 by mid-2026 and aims to advance additional candidates into IND-enabling studies, with ongoing investments in clinical manufacturing capabilities set to come online by the end of 2025.

Health Canada Authorization and Clinical Trials Initiation

AbCellera received Health Canada authorization to initiate their first two clinical trials for ABCL635 and ABCL575. Dosing has begun for ABCL635's Phase I trial evaluating its efficacy for vasomotor symptoms.

Strong Financial Position

AbCellera ended the quarter with approximately $750 million in available liquidity, including $580 million in cash and equivalents, and $170 million in committed government funding.

Pipeline Expansion

AbCellera advanced a third program, ABCL688, into IND-enabling studies and plans to advance at least one more development candidate by the end of 2025.

Revenue Growth

The company reported revenue of approximately $17 million for the quarter, up from $7 million in the same quarter of 2024.

AbCellera Biologics (ABCL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABCL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.14 / -	-0.17	―	―	―
Aug 07, 2025	2025 (Q2)	-0.13 / -0.12	-0.13	7.69% (+0.01)
May 08, 2025	2025 (Q1)	-0.14 / -0.15	-0.14	-7.14% (>-0.01)
Feb 27, 2025	2024 (Q4)	-0.13 / -0.12	-0.16	25.00% (+0.04)
Nov 04, 2024	2024 (Q3)	-0.12 / -0.17	-0.1	-70.00% (-0.07)
Aug 06, 2024	2024 (Q2)	-0.12 / -0.13	-0.11	-18.18% (-0.02)
May 07, 2024	2024 (Q1)	-0.13 / -0.14	-0.14	0.00% (0.00)
Feb 20, 2024	2023 (Q4)	-0.12 / -0.16	-0.1	-60.00% (-0.06)
Nov 02, 2023	2023 (Q3)	-0.12 / -0.10	0.08	-225.00% (-0.18)
Aug 03, 2023	2023 (Q2)	-0.13 / -0.11	-0.02	-450.00% (-0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ABCL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$4.24	$4.25	+0.24%
May 08, 2025	$2.01	$2.03	+1.00%
Feb 27, 2025	$2.92	$2.58	-11.64%
Nov 04, 2024	$2.89	$2.72	-5.88%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does AbCellera Biologics (ABCL) report earnings?

AbCellera Biologics (ABCL) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is AbCellera Biologics (ABCL) earnings time?

AbCellera Biologics (ABCL) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ABCL EPS forecast?

ABCL EPS forecast for the fiscal quarter 2025 (Q3) is -0.14.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing